Ergomed plc provided revenue guidance for the first half of 2018 and earnings guidance for the full year 2018. Demand for both clinical research services and drug safety and medical information segments remains generally buoyant. However, due to delays in the start-up of some contracts and reductions in scope by sponsors of others, revenue for the first half of 2018 is expected to be below management's expectations. From a profitability perspective, 2018 will be impacted by delayed revenues and the level of investment being made. The company believes it is prudent, therefore, to guide investors to expect adjusted EBITDA for 2018 to be only modestly ahead of 2017's adjusted EBITDA of £2.8 million. Revenue for the full year is now likely to be around 5% less than market consensus for 2018.